Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

Investors might want to bet on BioNTech SE Sponsored ADR (BNTX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

For 2025, BioNTech management anticipates revenue between 1.7 billion euros and 2.2 billion euros, with planned R&D outlays reaching between 2.6 billion euros and 2.8 billion euros. The company's ...

BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...

Yesterday, a German court ruled that Pfizer and BioNTech infringed Moderna's COVID-19 vaccine patent. The ruling required both PFE and BNTX to compensate the company, though the final amount will ...

Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seventeen analysts that are covering the firm, Marketbeat Ratings reports. Three ...

Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor ...

Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...

SVB Wealth LLC bought a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) in the fourth quarter, Holdings ...

In a report released today, Eliana Merle from UBS maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of ...

Another Medical stock, which has outperformed the sector so far this year, is BioNTech SE Sponsored ADR (BNTX). The stock has returned 7.8% year-to-date. The consensus estimate for BioNTech SE ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Legend Biotech (LEGN – Research Report) today. The company’s shares ...